We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

73 hedge funds and large institutions have $465M invested in Mirum Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more call options, than puts

Call options by funds: $1.1M | Put options by funds: $606K

67% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 9

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

15% more capital invested

Capital invested by funds: $405M → $465M (+$60.4M)

9% more funds holding

Funds holding: 6773 (+6)

10% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 21

0.36% less ownership

Funds ownership: 76.86%76.5% (-0.36%)

Holders
73
Holders Change
+6
Holders Change %
+8.96%
% of All Funds
1.28%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
15
Increased
23
Reduced
21
Closed
9
Calls
$1.1M
Puts
$606K
Net Calls
+$494K
Net Calls Change
+$494K
Name Holding Trade Value Shares
Change
Change in
Stake
NMC
1
NEA Management Company
Maryland
$83.4M
FM
2
Frazier Management
Washington
$71.1M
DM
3
Deerfield Management
New York
$65.4M -$2.7M -166,000 -5%
NHAS
4
Novo Holdings A/S
Denmark
$48.7M
RVM
5
RiverVest Venture Management
Missouri
$38.3M
RSCM
6
Rock Springs Capital Management
Maryland
$30.4M +$30.9K +1,900 +0.1%
Axa
7
Axa
France
$17M +$3.1M +190,580 +29%
Vanguard Group
8
Vanguard Group
Pennsylvania
$14.6M +$51.2K +3,150 +0.4%
BBA
9
Baker Bros. Advisors
New York
$12.9M
BlackRock
10
BlackRock
New York
$12.2M +$46K +2,831 +0.5%
BI
11
BVF Inc
California
$8.68M +$7.09M +435,936 New
Wellington Management Group
12
Wellington Management Group
Massachusetts
$7.26M +$304K +18,700 +5%
MB
13
MPM BioImpact
Massachusetts
$6.15M +$5.02M +308,532 New
SCM
14
Sio Capital Management
New York
$4.96M -$3.35M -205,914 -45%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$3.52M +$39.1K +2,402 +1%
Jacobs Levy Equity Management
16
Jacobs Levy Equity Management
New Jersey
$3.27M +$1.49M +91,669 +126%
Two Sigma Investments
17
Two Sigma Investments
New York
$3.09M +$998K +61,360 +65%
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$2.88M +$2.04M +125,600 +668%
Millennium Management
19
Millennium Management
New York
$2.64M +$1.42M +87,615 +195%
State Street
20
State Street
Massachusetts
$2.53M +$21.2K +1,303 +1%
Ensign Peak Advisors
21
Ensign Peak Advisors
Utah
$2.52M
Two Sigma Advisers
22
Two Sigma Advisers
New York
$1.86M +$190K +11,700 +14%
Northern Trust
23
Northern Trust
Illinois
$1.77M -$118K -7,233 -8%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$1.74M +$1.25M +76,987 +739%
Citadel Advisors
25
Citadel Advisors
Florida
$1.72M +$1.41M +86,478 New

MIRM Hedge Fund Activity: Q3 2021 in Review

73 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2021, worth a combined $465M — up 15% from $405M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new MIRM positions and 9 closed out — a net gain of 6 holders — while 23 added to existing stakes and 21 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $7.09M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $6.45M sold.

  • 73 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2021, up from 67 in Q2 2021.
  • Funds reported $465M of Mirum Pharmaceuticals stock for Q3 2021, up 15% quarter-over-quarter.
  • 15 funds opened new Mirum Pharmaceuticals positions in Q3 2021 and 9 closed out, a net change of +6 holders.
  • The largest Mirum Pharmaceuticals buyer in Q3 2021 was BVF Inc, an estimated $7.09M added.
  • The largest Mirum Pharmaceuticals seller in Q3 2021 was Driehaus Capital Management, an estimated $6.45M sold.

Based on aggregated 13F filings for Q3 2021.